Consensus MoonLake Immunotherapeutics

Equities

MLTX

KY61559X1045

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
40.92 ^USD	-2.50%		-9.59%	-32.24%

May. 07	MoonLake Immunotherapeutics Q1 Net Loss Widens	MT
May. 07	MoonLake Immunotherapeutics Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Evolution of the average Target Price on MoonLake Immunotherapeutics

Price target over the last 5 years

History of analyst recommendation changes

19b7559dd8c3c2b3ff6ab.dIna5sXwMYmm7ccZKI0fZHZnxykHSNtJy-vu7kusC5Y.E7yohKzJR_iSuL97ZPgtNUI0sl1lG5Ervp2NmnjgP6Q64rastaVk2-vbjg~c2290eddc6d2fd912c9ac98af022954d

Analyst Recommendations on MoonLake Immunotherapeutics

Goldman Sachs Initiates MoonLake Immunotherapeutics at Neutral With $62 Price Target	Apr. 02	MT
HC Wainwright Adjusts Price Target on MoonLake Immunotherapeutics to $100 From $75, Maintains Buy Rating	Mar. 11	MT
Wolfe Research Initiates MoonLake Immunotherapeutics With Outperform Rating, $77 Price Target	Feb. 15	MT
Stifel Adjusts Price Target on MoonLake Immunotherapeutics to $69 From $66, Maintains Buy Rating	Dec. 18	MT
Citigroup Starts MoonLake Immunotherapeutics With Buy Rating, $72 Price Target	Dec. 08	MT
Wedbush Raises MoonLake Immunotherapeutics' Price Target to $92 From $86, Maintains Outperform Rating	Nov. 16	MT
Guggenheim Adjusts MoonLake Immunotherapeutics' Price Target to $77 From $70, Maintains Buy Rating	Nov. 14	MT
Barclays Adjusts MoonLake Immunotherapeutics' Price Target to $59 From $41, Keeps Equalweight Rating	23-09-12	MT
Needham Starts MoonLake Immunotherapeutics at Buy With $76 Price Target	23-08-31	MT
Wedbush Raises MoonLake Immunotherapeutics' PT to $86 From $61, Revisits Valuation Ahead of Data Readouts Expected in Q4; Keeps Outperform Rating	23-07-31	MT
HC Wainwright Adjusts MoonLake Immunotherapeutics Price Target to $75 From $37, Maintains Buy Rating	23-07-17	MT
Cantor Fitzgerald Raises Price Target on MoonLake Immunotherapeutics to $65 From $29, Maintains Overweight Rating	23-07-03	MT
Wedbush Raises MoonLake Immunotherapeutics' PT to $61 From $33 After Positive Topline Phase 2 MIRA Results, Keeps Outperform Rating	23-06-27	MT
Barclays Adjusts Price Target on MoonLake Immunotherapeutics to $41 From $28, Keeps Equalweight Rating	23-06-27	MT
Wedbush Raises MoonLake Immunotherapeutics' PT to $61 From $33 After Positive Topline Phase 2 MIRA Results, Keeps Outperform Rating	23-06-27	MT
Lifesci Capital Raises MoonLake Immunotherapeutics' Price Target to $60 From $36, Outperform Rating Retained	23-06-26	MT
Jefferies Raises MoonLake Immunotherapeutics' Price Target to $58 From $30, Maintains Buy Rating	23-06-26	MT
Guggenheim Adjusts Price Target on MoonLake Immunotherapeutics to $65 From $51, Maintains Buy Rating	23-06-26	MT
Barclays Initiates MoonLake Immunotherapeutics With Equalweight Rating, $28 Price Target	23-06-15	MT
Guggenheim Starts MoonLake Immunotherapeutics at Buy With $51 Price Target	23-05-01	MT
HC Wainwright Adjusts Price Target on MoonLake Immunotherapeutics to $30 From $28, Maintains Buy Rating	23-04-20	MT
Wedbush Starts MoonLake Immunotherapeutics at Outperform With PT of $33, Highlights Potential for Best-in-Class Nanobody Therapy	23-03-22	MT
Wedbush Starts MoonLake Immunotherapeutics at Outperform With Price Target of $33	23-03-22	MT
Wedbush Initiates Coverage on MoonLake Immunotherapeutics With Outperform Rating, $33 Price Target	23-03-22	MT
Cantor Fitzgerald Adjusts Price Target on MoonLake Immunotherapeutics to $29 From $23, Keeps Overweight Rating	23-03-20	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

40.92 USD

Average target price

73.38 USD

Spread / Average Target

+79.34%

High Price Target

100 USD

Spread / Highest target

+144.38%

Low Price Target

55 USD

Spread / Lowest Target

+34.41%

Consensus detail

Consensus revision (last 18 months)

Analysts covering MoonLake Immunotherapeutics

Goldman Sachs
HC Wainwright
Wolfe Research
Stifel Nicolaus
Citigroup
Wedbush
Guggenheim
Barclays
Needham & Co.
Cantor Fitzgerald
Jefferies & Co.
LifeSci Capital
BTIG
SVB Securities LLC
Cowen

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar